Monoclonal antibody treatment step in fight against childhood cancer

Benita Zahn & WNYT Staff
Updated: January 28, 2021 06:47 PM
Created: January 28, 2021 06:46 PM

Cancer in children is a rare occurrence. Seven to 10% of childhood cancers are neuroblastomas.

Because it's so difficult to treat, any new drug is welcome.

A new monoclonal antibody was approved in late November. Its trade name is Danyelza.

For those on the treatment frontlines, it's welcome news.

Neuroblastoma is a nerve based tumor but not a brain tumor.

Some 800 cases a year of neuroblastoma are diagnosed in the U.S. It accounts for 50% of all cancers in infants, making it the most common tumor in infants younger than one year.

Most children with neuroblastoma are diagnosed before age 5. Slightly more boys than girls are affected. About 50% of the children affected will already have metastatic or widespread disease. However, every child will face a grueling battle.

Learn more about how Danyelza works, and how much doctors think it could help by watching the video of Benita Zahn's story.

Copyright 2021 - WNYT-TV, LLC A Hubbard Broadcasting Company

Comment on Facebook